Clinical Trial Update: Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial update assessing long-acting octreotide (Sandostatin LAR) for reducing portal pressure in patients with cirrhosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Esophageal Varices
• Portal Hypertension

Drugs mentioned

• Sandostatin LAR (octreotide)

Snippet

Sponsor: Mayo Clinic | Conditions: Cirrhosis, Portal Hypertension | Phase 1, Phase 2 | Status: COMPLETED